Abstract
Background: In patients with uncontrolled asthma despite ICS/LABA, effects of adding LAMA and/or increasing ICS on lung function may differ.
Aim: Evaluate the impact of adding LAMA (UMEC) and/or increasing ICS (FF) dose to ICS/LABA (FF/VI) on the proportion of patients achieving a trough FEV1 response of ≥100mL at Week 24.
Methods: CAPTAIN: Phase IIIA, randomised, double-blind, 24–52-week, parallel-group study in adults with uncontrolled asthma on ICS/LABA. Treatment: FF/VI (100/25, 200/25μg) or FF/UMEC/VI (100/31.25/25, 100/62.5/25, 200/31.25/25, 200/62.5/25μg) QD (ELLIPTA). Outcomes: proportion of patients with ≥100mL improvement in trough FEV1 from baseline at Week 24 (prespecified analysis). Data for UMEC 62.5μg only are shown here.
Results: Addition of UMEC 62.5μg to FF/VI 100/25μg or 200/25μg was associated with an increase in the proportion of patients with ≥100mL improvement from baseline in trough FEV1 (FEV1 responders). Doubling ICS dose in dual and triple therapy had a lesser effect. However, the greatest increase in FEV1 responders was observed in the simultaneous step-up group (Fig 1).
Conclusions: Addition of a LAMA, UMEC, to ICS/LABA as single-inhaler triple therapy increased the proportion of FEV1 responders. Simultaneous doubling of the FF dose and addition of UMEC had the greatest impact on FEV1 response.
Funding: GSK (205715/NCT02924688).
Footnotes
Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3386.
This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2021
